Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer

Clinica Chimica Acta

Volumn 455, Issue , 2016, Pages 26-32

  Yörüker, Ebru E ^a   Holdenrieder, Stefan ^b   Gezer, Ugur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Blood based biomarkers; Cell free DNA; Circulating tumor cells; Colorectal cancer; DNA methylation; Histone methylation; Liquid biopsy; Point mutations

Indexed keywords

APC PROTEIN; CARCINOEMBRYONIC ANTIGEN; CELL FREE DNA; DNA; MESSENGER RNA; MICRORNA; RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

APC GENE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; CIRCULATING TUMOR CELL; COLORECTAL CANCER; DNA METHYLATION; EARLY DIAGNOSIS; GENE EXPRESSION; HISTONE METHYLATION; HUMAN; MICROSATELLITE MARKER; NUCLEOSOME; PATIENT MONITORING; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; BLOOD; COLORECTAL NEOPLASMS; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA, NEOPLASM; HUMANS; PROGNOSIS; RNA, NEOPLASM;

EID: 84955480711     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.01.016     Document Type: Review

References (114)

1. Siegel R., Desantis C., Jemal A. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:104-117.
2. Smith R.A., Manassaram-Baptiste D., Brooks D., Doroshenk M., Fedewa S., Saslow D., et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J. Clin. 2015, 65:30-54.
3. Pino M.S., Chung D.C. The chromosomal instability pathway in colon cancer. Gastroenterology 2010, 138:2059-2072.
4. Rawson J.B., Bapat B. Epigenetic biomarkers in colorectal cancer diagnostics. Expert. Rev. Mol. Diagn. 2012, 12:499-509.
5. Newton K.F., Newman W., Hill J. Review of biomarkers in colorectal cancer. Color. Dis. 2012, 14:3-17.
6. Asworth T.R. A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust. Med. J. 1869, 14:146-149.
7. Alix-Panabières C., Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin. Chem. 2013, 59:110-118.
8. Hong B., Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics 2013, 3:377-394.
9. Armstrong A.J., Marengo M.S., Oltean S., Kemeny G., Bitting R.L., Turnbull J.D., et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 2011, 9:997-1007.
10. Kokkinos M.I., Wafai R., Wong M.K., Newgreen D.F., Thompson E.W., Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 2007, 185:191-203.
11. Wicha M.S., Hayes D.F. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol. 2011, 29:1508-1511.
12. Yokobori T., Iinuma H., Shimamura T., Imoto S., Sugimachi K., Ishii H., et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013, 73:2059-2069.
13. Lyberopoulou A., Aravantinos G., Efstathopoulos E.P., Nikiteas N., Bouziotis P., Isaakidou A., et al. Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. PLoS One 2015, 22.
14. Mostert B., Jiang Y., Sieuwerts A.M., Wang H., Bolt-de Vries J., Biermann K., et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int. J. Cancer 2013, 133:130-141.
15. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 2009, 20:1223-1229.
16. Barbazán J., Vieito M., Abalo A., Alonso-Alconada L., Muinelo-Romay L., Alonso-Nocelo M., et al. A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer. J. Cell. Mol. Med. 2012, 16:2342-2349.
17. Akagi Y., Kinugasa T., Adachi Y., Shirouzu K. Prognostic significance of isolated tumor cells in patients with colorectal cancer in recent 10-year studies. Mol. Clin. Oncol. 2013, 1:582-592.
18. Mandel P., Metais P. Les acides nucleiques du plasma sanguin chez l'homme. C. R. Seances Soc. Biol. Fil. 1948, 142:241-243.
19. Moreira V.G., Prieto B., Rodriguez J.S., Alvarez F.V. Usefulness of cellfree plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann. Clin. Biochem. 2010, 47:253-258.
20. Zhong X.Y., von Mühlenen I., Li Y., Kang A., Gupta A.K., Tyndall A., et al. Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Clin. Chem. 2007, 53:1609-1614.
21. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.
22. Holdenrieder S., Stieber P. Clinical use of circulating nucleosomes. Crit. Rev. Clin. Lab. Sci. 2009, 46:1-24.
23. Frattini M., Gallino G., Signoroni S., Balestra D., Battaglia L., Sozzi G., et al. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann. N. Y. Acad. Sci. 2006, 1075:185-190.
24. Boni L., Cassinotti E., Canziani M., Dionigi G., Rovera F., Dionigi R. Free circulating DNA as possible tumour marker in colorectal cancer. Surg. Oncol. 2007, 16:29-31.
25. Schwarzenbach H., Stoehlmacher J., Pantel K., Goekkurt E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann. N. Y. Acad. Sci. 2008, 1137:190-196.
26. Yu J., Gu G., Ju S. Recent advances in clinical applications of circulating cell-free DNA integrity. Lab. Med. 2014, 45:6-11.
27. Umetani N., Kim J., Hiramatsu S., Reber H.A., Hines O.J., Bilchik A.J., et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 2006, 52:1062-1069.
28. Da Silva Filho B.F., Gurgel A.P., Neto M.Á., de Azevedo D.A., de Freitas A.C., Silva Neto Jda C., et al. Circulating cell-free DNA in serum as a biomarker of colorectal cancer. J. Clin. Pathol. 2013, 66:775-778.
29. Leszinski G., Lehner J., Gezer U., Holdenrieder S. Increased DNA integrity in colorectal cancer. In Vivo 2014, 28:299-303.
30. Mouliere F., Robert B., Arnau Peyrotte E., del Rio M., Ychoum, Molina F., et al. High fragmentation characterizes tumor-derived circulating DNA. PLoS One 2011, 6.
31. Mead R., Duku M., Bhandari P., Cree I.A. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br. J. Cancer 2011, 105:239-245.
32. Mouliere F., El Messaoudi S., Pang D., Dritschilo A., Thierry A.R. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol. Oncol. 2014, 8:927-941.
33. Yörüker E.E., Özgür E., Keskin M., Dalay N., Holdenrieder S., Gezer U. Assessment of circulating serum DNA integrity in colorectal cancer patients. Anticancer Res. 2015, 35:2435-2440.
34. Hao T.B., Shi W., Shen X.J., Qi J., Wu X.H., Wu Y., et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br. J. Cancer 2014, 111:1482-1489.
35. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998, 58:5248-5257.
36. Kim G.P., Colangelo L.H., Wieand H.S., Paik S., Kirsch I.R., Wolmark N., et al. Prognostic and predictive roles of high degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 2007, 25:767-772.
37. Hibi K., Robinson C.R., Booker S., Wu L., Hamilton S.R., Sidransky D., et al. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res. 1998, 58:1405-1407.
38. Kölble K., Ullrich O.M., Pidde H., Barthel B., Diermann J., Rudolph B., et al. Microsatellite alterations in serum DNA of patients with colorectal cancer. Lab. Investig. 1999, 79:1145-1150.
39. Taback B., Saha S., Hoon D.S. Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients. Ann. N. Y. Acad. Sci. 2006, 1075:197-203.
40. Lazarev I., Leibovitch L., Czeiger D., Sion-Vardi N., Geffen D.B., Douvdevani A., et al. Cell-free DNA blood levels in colorectal cancer patients do not correlate with mismatch repair-proficiency. In Vivo 2014, 28:349-354.
41. Ling E., Fich A., Man S., Wolfson M., Mikhailowsky R., Lamprecht S.A. Detection of tumor mutant APC DNA in plasma of patients with sporadic colorectal cancer. In Vivo 2000, 14:543-546.
42. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16368-16373.
43. Wang J.Y., Hsieh J.S., Chang M.Y., Huang T.J., Chen F.M., Cheng T.L., et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J. Surg. 2004, 28:72172-72176.
44. Lecomte T., Berger A., Zinzindohoué F., Micard S., Landi B., Blons H., et al. Detection of free-circulating tumor-associated DNA in serum of colorectal cancer patients and its association with prognosis. Int. J. Cancer 2002, 100:542-548.
45. Boni L., Cassinotti E., Canziani M., Dionigi G., Rovera F., Dionigi R. Free circulating DNA as possible tumor marker in colorectal cancer. Surg. Oncol. 2007, 16:29-31.
46. Flamini E., Mercatali L., Nanni O., Calistri D., Nunziatini R., Zoli W., et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin. Cancer Res. 2006, 12:6985-6988.
47. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
48. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358:1160-1174.
49. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
50. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
51. Heinemann V., Stintzing S., Kirchner T., Boeck S., Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat. Rev. 2009, 35:262-271.
52. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations of the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
53. Bazan V., Bruno L., Augello C., Agnese V., Calò V., Corsale S., et al. Molecular detection of TP53, KRAS and p16 promoter methylation in serum of patients with colorectal cancer and its association with prognosis. Results of a 3years GOIM (gruppo oncologico dell'italia meridionale) prospective study. Ann. Oncol. 2006, 17:784-790.
54. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14:985-990.
55. Trevisiol C., Di Fabio F., Nascimbeni R., Peloso L., Salbe C., Ferruzzi E., Salerni B., et al. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. Int. J. Biol. Markers 2006, 21:223-228.
56. Lefebure B., Charbonnier F., Di Fiore F., Tuech J.J., Le Pessot F., Michot F., et al. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. Ann. Surg. 2010, 251:275-280.
57. Taly V., Pekin D., Benhaim L., Kotsopoulos S.K., Le Corre D., Li X., et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 2013, 59:1722-1731.
58. Selaru F.M., David S., Meltzer S.J., Hamilton J.P. Epigenetic events in gastrointestinal cancer. Am. J. Gastroenterol. 2009, 104:1910-1912.
59. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009, 1:239-259.
60. Mu W.P., Wang J., Niu Q., Shi N., Lian H.F. Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis. Oncol. Targets Ther. 2014, 7:1237-1245.
61. Wang Y., Long Y., Xu Y., Guan Z., Lian P., Peng J., et al. Prognostic and predictive value of CpG island methylator phenotype in patients with locally advanced nonmetastatic sporadic colorectal cancer. Gastroenterol. Res. Pract. 2014, 2014:436985.
62. Benard A., Zeestraten E.C., Goossens-Beumer I.J., Putter H., van de Velde C.J., Hoon D.S., et al. DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence. Apoptosis 2014, 19:1581-1593.
63. Deng D., Liu Z., Du Y. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. Adv. Genet. 2010, 71:125-176.
64. Grützmann R., Molnar B., Pilarsky C., Habermann J.K., Schlag P.M., Saeger H.D., et al. Sensitive detection ofcolorectal cancer in peripheral blood by septin 9 DNA methylationassay. PLoS One 2008, 3.
65. Warren J.D., Xiong W., Bunker A.M., Vaughn C.P., Furtado L.V., Roberts W.L., et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011, 9:133.
66. Church T.R., Wandell M., Lofton-Day C., Mongin S.J., Burger M., Payne S.R., et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014, 63:317-325.
67. Herbst A., Rahmig K., Stieber P., Philipp A., Jung A., Ofner A., et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am. J. Gastroenterol. 2011, 106:1110-1118.
68. Suzuki H., Yamamoto E., Maruyama R., Niinuma T., Kai M. Biological significance of the CpG island methylator phenotype. Biochem. Biophys. Res. Commun. 2014, 455:35-42.
69. Tan S.H., Ida H., Lau Q.C., Goh B.C., Chieng W.S., Loh M., et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol. Rep. 2007, 18:1225-1230.
70. Holdenrieder S., Dharuman Y., Standop J., Trimpop N., Herzog M., Hettwer K., et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer. Anticancer Res. 2014, 34:2357-2362.
71. Herbst A., Wallner M., Rahmig K., Stieber P., Crispin A., Lamerz R., et al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur. J. Gastroenterol. Hepatol. 2009, 21:565-569.
72. Wallner M., Herbst A., Behrens A., Crispin A., Stieber P., Göke B., et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res. 2006, 12:7347-7352.
73. Kim M.S., Chang X., Yamashita K., Nagpal J.K., Baek J.H., Wu G., et al. Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma. Oncogene 2008, 27:3624-3634.
74. Ahlquist D.A., Taylor W.R., Mahoney D.W., Zou H., Domanico M., Thibodeau S.N., et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol. 2012, 10:272-277.
75. Shen J., Stass S.A., Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013, 329:125-136.
76. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56:1733-1741.
77. Xu D., Li X.F., Zheng S., Jiang W.Z. Quantitative real-time RT-PCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients. J. Zhejiang Univ. (Sci.) 2006, 7:445-451.
78. Shen C., Hu L., Xia L., Li Y. Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. Jpn. J. Clin. Oncol. 2008, 38:770-776.
79. Tsouma A., Aggeli C., Lembessis P., Zografos G.N., Korkolis D.P., Pectasides D., et al. Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J. Gastroenterol. 2010, 21:5965-5974.
80. Ganepola G.A., Nizin J., Rutledge J.R., Chang D.H. Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. World J. Gastrointest. Oncol. 2014, 6:83-97.
81. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 2011, 8:467-477.
82. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
83. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11:849-864.
84. Slack F.J. MicroRNAs regulate expression of oncogenes. Clin. Chem. 2013, 59:325-326.
85. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
86. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
87. Berger F., Reiser M.F. Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences?. Theranostics 2013, 3:943-952.
88. Wang B., Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J. Cancer Res. Clin. Oncol. 2012, 138:1659-1666.
89. Zhang J., Zhang K., Bi M., Jiao X., Zhang D., Dong Q. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anti-Cancer Drugs 2014, 25:346-352.
90. Liu G.H., Zhou Z.G., Chen R., MJ W., Y L., XF S. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013, 34:2175-2181.
91. Yang Y., Peng W., Tang T., Xia L., Wang X.D., Duan B.F., et al. MicroRNAs as promising biomarkers for tumor-staging: evaluation of MiR21 MiR155 MiR29a and MiR92a in predicting tumor stage of rectal cancer. Asian Pac. J. Cancer Prev. 2014, 15:5175-5180.
92. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 2010, 127:118-126.
93. Wang Q., Huang Z., Ni S., Xiao X., Xu Q., Wang L., et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 2012, 7.
94. Giráldez M.D., Lozano J.J., Ramírez G., Hijona E., Bujanda L., Castells A., et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin. Gastroenterol. Hepatol. 2013, 11:681-688.
95. Wang S., Xiang J., Li Z., Lu S., Hu J., Gao X., et al. A plasma microRNA panel for early detection of colorectal cancer. Int. J. Cancer 2015, 136:152-161.
96. Wang J., Huang S.K., Zhao M., Yang M., Zhong J.L., Gu Y.Y., et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One 2014, 9.
97. Hofsli E., Sjursen W., Prestvik W.S., Johansen J., Rye M., Tranø G., et al. Identification of serum microRNA profiles in colon cancer. Br. J. Cancer 2013, 108:1712-1719.
98. Kanaan Z., Roberts H., Eichenberger M.R., Billeter A., Ocheretner G., Pan J., et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann. Surg. 2013, 258:400-408.
99. Toiyama Y., Hur K., Tanaka K., Inoue Y., Kusunoki M., et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann. Surg. 2014, 259:735-743.
100. Cheng H., Zhang L., Cogdell D.E., Zheng H., Schetter A.J., Nykter M., et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011, 6.
101. Menéndez P., Padilla D., Villarejo P., Palomino T., Nieto P., Menéndez J.M., et al. Prognostic implications of serum microRNA-21 in colorectal cancer. J. Surg. Oncol. 2013, 108:369-373.
102. Pu X.X., Huang G.L., Guo H.Q., Guo C.C., Li H., Ye S., et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J. Gastroenterol. Hepatol. 2010, 25:1674-1680.
103. Chen Q., Xia H.W., Ge X.J., Zhang Y.C., Tang Q.L., Bi F. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac. J. Cancer Prev. 2013, 14:7421-7426.
104. Kjersem J.B., Ikdahl T., Lingjaerde O.C., Guren T., Tveit K.M., Kure E.H. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol. Oncol. 2014, 8:59-67.
105. Hundt S., Haug U., Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol. Biomark. Prev. 2007, 16:1935.
106. Duffy M.J. Personalized treatment for patients with colorectal cancer: role of biomarkers. Biomark. Med 2015, 9:337-347.
107. Van der Vaart M., PJ P. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated. Clin. Biochem. 2010, 43:26-36.
108. Stoetzer O.J., Wittwer C., Lehner J., Fahmueller Y.N., Kohles N., Fersching D.M., et al. Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy. Expert. Opin. Biol. Ther. 2012, 12:S217-S224.
109. Gezer U., Holdenrieder S. Post-translational histone modifications in circulating nucleosomes as new biomarkers in colorectal cancer. In Vivo 2014, 28:287-292.
110. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., et al. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
111. Deligezer U., Akisik E.E., Erten N., Dalay N. Sequence-specific histone methylation is detectable on circulating nucleosomes in plasma. Clin. Chem. 2008, 54:1125-1131.
112. Leszinski G., Gezer U., Siegele B., Stoetzer O., Holdenrieder S. Relevance of histone marks H3K9me3 and H4K20me3 in cancer. Anticancer Res. 2012, 32:2199-2205.
113. Gezer U., Ustek D., Yörüker E.E., Cakiris A., Abaci N., Leszinski G., Dalay N., Holdenrieder S. Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumour Biol. 2013, 34:329-336.
114. Gezer U., Yörüker E.E., Keskin M., Kulle C.B., Dharumann N., Holdenrieder S. Histon methylation marks on circulating nucleosomes as novel blood-based biomarkers in colorectal cancer. Int. J. Mol. Sci. 2015, 16:29654-29662.